This research examines a specific type of cancer treatment called immunotherapy for patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer. This is a common form of the disease. The study combined data from many different groups to look at how well this treatment works compared to standard care or no treatment. The goal was to see if adding immunotherapy helps patients live longer or feel better.
The researchers looked at 7,480 patients in total. They tracked how the cancer responded to the treatment over a period of about six and a half months. They measured several important outcomes, including whether the tumor shrank, how long the cancer stayed under control, and how many people died during the study period. They also carefully watched for any side effects caused by the drugs.
The main finding regarding overall survival was that immunotherapy did not significantly improve results compared to the control group. The data showed a relative risk of 1.20 with a confidence interval ranging from 0.92 to 1.55. In plain terms, this means the treatment did not lead to a clear survival benefit for the group as a whole. Similarly, the partial response rate, which measures how many tumors shrank by a certain amount, did not show a significant improvement. The relative risk was 1.03 with a wide confidence interval from 0.54 to 1.94.
However, there was one area where the treatment showed a positive sign. Immunotherapy was associated with improved complete response rates. The relative risk was 1.63 with a confidence interval from 1.34 to 1.97. This suggests that when the treatment did work, it was quite effective at completely clearing the cancer in those specific cases. The pooled rate for complete response was 9 percent, while partial response was 27 percent and stable disease was 51 percent.
Safety was a major concern in this analysis. The study found that patients receiving immunotherapy experienced higher rates of therapy-related adverse events. The relative risk was 1.29 with a confidence interval from 1.04 to 1.60. This means the treatment caused more side effects than the control group. The study did not report specific details on serious adverse events or discontinuations, but the increase in general side effects is a notable finding.
The pooled median overall survival was 23.6 months and the pooled median progression-free survival was 6.6 months. These numbers represent the average time patients lived or stayed disease-free in the combined data. The overall mortality rate for the immunotherapy group was 4 percent. It is important to remember that this is a meta-analysis of existing data. The study does not prove that immunotherapy causes these results, but rather shows a link between the treatment and these outcomes. Patients should not change their treatment plans based on this single analysis. Doctors will consider all factors before recommending a new therapy.